OTTAWA, May 16, 2017 /CNW/ - Federal Health Minister Dr. Jane Philpott's announcement todayat the Economic Club of Canada on "improving affordability, accessibility and appropriate use of drugs in Canada," may well have a profound impact on drug prices in the country.
Dr. Philpott announced today the following important drug pricing policy changes:
Binder said of the announcement, "Patients requiring effective but high cost drugs for life threatening conditions, including oncology, certainly support steps to moderate prices and ensure access to all people in Canada who need them. As always, the devil is in the details. We are pleased that the Minister committed to meaningful patient engagement at every step in the process."
"Myeloma patients support this direction. We trust that savings will go directly back into the health care system to enhance further innovation in healthcare and access to necessary treatments," said Martine Elias, the Director of Access, Advocacy and Community Relations at Myeloma Canada and a member of the Drug Pricing Policy Working Groups. "We also want to ensure that research and innovation of new drugs continue in Canada."
The many patient organizations participating in the Drug Pricing Policy Working Groups encourage relevant stakeholders to reconsider the way we measure the value of potential lifesaving drugs, enhance drug access in Canada and address high priced pharmaceuticals.
SOURCE Save Your Skin Foundation
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All